Sanofi goes back to Scribe
The latest deal focuses on in vivo Crispr editing for sickle cell disease, and follows last year’s cancer collaboration.
Lilly goes cellular for $34m
And conveniently, Celltrans blazes a trail for cell therapies in diabetes.
Lilly gambles on Dice
Lilly follows others into the oral autoimmune space, not long after its leader questioned the future of small molecules.
Lilly signs up Verve to take on Novartis and Amgen
Today’s $60m deal is focused on Lp(a), a new cardiovascular target for the gene editing company.
Novartis takes the helicopter view on Chinook
After Calliditas and Travere secure US approvals Novartis doubles down on a rare kidney disease, but what will the FTC say?